S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study will attempt to determine the feasibility of combination of Oxaliplatin,
Irinotecan, and S-1, the maximum tolerated dose and the recommended doses of the agents used,
and to preliminarily evaluate the antitumor activity in untreated patients with advanced
gastrointestinal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Hallym University Medical Center
Collaborators:
CJ HealthCare Corporation Handok Inc. Handok Pharmaceuticals Co., Ltd. HK inno.N Corporation Jeil Pharmaceutical Co., Ltd. Pfizer